Citations (80)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Sepehr Farahbakhshian, Qi Fan, Bob G. Schultz, Nicole Princic, Julie Park & Michael Bullano. (2023) Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data. Journal of Medical Economics 26:1, pages 1278-1286.
Read now
Read now
Randall Curtis, Marilyn Manco-Johnson, Barbara A Konkle, Roshni Kulkarni, Joanne Wu, Judith R Baker, Megan Ullman, Duc Quang Tran Jr & Michael B Nichol. (2022) Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophilia—Hematology Utilization Group Study Part VII (HUGS VII). Journal of Blood Medicine 13, pages 229-241.
Read now
Read now
Lorraine Cafuir, Adina Estrin, Er Chen, David Hinds, Patricia Prince, Jennifer Thorburn, Henry Mead & Christine L. Kempton. (2022) Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors. Journal of Medical Economics 25:1, pages 984-992.
Read now
Read now
Xiaoli Niu, Carole Dembek, Qi Fan, Yongcai Mao, Victoria Divino, Steven Burch & Michael Tocco. (2022) The impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis. Journal of Medical Economics 25:1, pages 152-159.
Read now
Read now
T. Joseph Mattingly$suffix/text()$suffix/text(), Valeria Diaz Fernandez, Dominique Seo & Andrea I. Melgar Castillo. (2022) A review of caregiver costs included in cost-of-illness studies. Expert Review of Pharmacoeconomics & Outcomes Research 22:7, pages 1051-1060.
Read now
Read now
Nikoletta M. Margaretos, Anisha M. Patel, Ari D. Panzer, Rachel C. Lai, Jennifer Whiteley & James D. Chambers. (2021) Variation in access to hemophilia A treatments in the United States. Journal of Medical Economics 24:1, pages 1143-1148.
Read now
Read now
Keziah Cook, Shaun P. Forbes, Kelly Adamski, Janice J. Ma, Anita Chawla & Louis P. Garrison$suffix/text()$suffix/text(). (2020) Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. Journal of Medical Economics 23:5, pages 501-512.
Read now
Read now
Khosro Keshavarz, Mohammadreza Bordbar, Zeinab Hashemipoor, Farideh Sadat Jalali & Ramin Ravangard. (2020) Economic burden of hemophilia A and B: a case in Iran. Hematology 25:1, pages 149-155.
Read now
Read now
Giovanni Di Minno, Elena Santagostino, Massimo Morfini, Cosimo Ettorre, Dorina Cultrera, Erminia Baldacci, Eleonora Russo & Cristiano Gallucci. (2019) Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A. Patient Preference and Adherence 13, pages 233-240.
Read now
Read now
Anisha M. Patel, Shelby L. Corman, Stephen Chaplin, Karina Raimundo & Robert F. Sidonio. (2019) Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. Journal of Medical Economics 22:12, pages 1328-1337.
Read now
Read now
Jason P. Swindle, Yaping Xu, Yunming Mu & Paul G. Solari. (2019) Healthcare costs among patients with hemophilia A treated with factor replacement or bypassing agents. Current Medical Research and Opinion 35:8, pages 1433-1440.
Read now
Read now
Articles from other publishers (69)
Lisa Young, Yong Chen, José Alvir, Tom Burke, Enrico Ferri Grazzi & Ian Winburn. (2023) The impact of bleeding event frequency on health-related quality of life and work productivity outcomes in a European cohort of adults with haemophilia A: insights from the CHESS II study. Orphanet Journal of Rare Diseases 18:1.
Crossref
Crossref
Yilin ChenSpencer J ChengTyler ThornhillPaul SolariSean D Sullivan. (2023) Health care costs and resource use of managing hemophilia A: A targeted literature review. Journal of Managed Care & Specialty Pharmacy 29:6, pages 647-658.
Crossref
Crossref
Sara Guasch, Lia C. Scott, Janet Figueroa, Tyler W. Buckner, Shanna Mattis, Duc Q. TranJrJr & Christine L. Kempton. (2023) Cross‐sectional study evaluating the association of haemophilia‐related distress and clinically relevant outcomes. Haemophilia 29:2, pages 505-512.
Crossref
Crossref
Nana Kragh, Anna Tytula, Michał Pochopien, Samuel Aballéa, Mondher Toumi, Zalmai Hakimi, Jameel Nazir, Linda Bystrická & Francis Fatoye. (2022)
Cost‐effectiveness of recombinant factor
VIII Fc
versus emicizumab for prophylaxis in adults and adolescents with haemophilia
A
without inhibitors in the
UK
. European Journal of Haematology 110:3, pages 262-270.
Crossref
Crossref
Sofie Persson, Cecilia Berndt, Sara Engstrand, Annegret Trinczek, Katarina Steen Carlsson & Erik Berntorp. (2022) Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A. Haemophilia 29:1, pages 145-155.
Crossref
Crossref
Ritu M. Ramamurthy, Martin Rodriguez, Hannah C. Ainsworth, Jordan Shields, Diane Meares, Colin Bishop, Andrew Farland, Carl D. Langefeld, Anthony Atala, Christopher B. Doering, H. Trent Spencer, Christopher D. Porada & Graça Almeida-Porada. (2022) Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII. Frontiers in Immunology 13.
Crossref
Crossref
Gabriela G Yamaguti-Hayakawa & Margareth C Ozelo. (2023) Gene therapy for hemophilia: looking beyond factor expression. Experimental Biology and Medicine 247:24, pages 2223-2232.
Crossref
Crossref
Jyoti Rana, Maite Melero Muñoz & Moanaro Biswas. (2022) Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies. Cellular Immunology 382, pages 104641.
Crossref
Crossref
Azusa Nagao, Akiko Ioka, Takao Nakamura, Yoichi Murakami, Misako Makishima, Norihiro Okada & Michio Sakai. (2022) Burden of congenital hemophilia A requiring treatment in Japan: The HIKOBOSHI study. Research and Practice in Thrombosis and Haemostasis 6:7, pages e12825.
Crossref
Crossref
Giancarlo Castaman, Giovanni Di Minno, Raimondo De Cristofaro & Flora Peyvandi. (2022) The Arrival of Gene Therapy for Patients with Hemophilia A. International Journal of Molecular Sciences 23:18, pages 10228.
Crossref
Crossref
Xiaoning He, Xu Wang, Chaohui Dong, Mingyue Zhao & Jing Wu. (2022) The long‐term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population‐based predictions from 2018 to 2033. Haemophilia 28:5, pages 726-736.
Crossref
Crossref
Fabienne R. Kloosterman, Anne-Fleur Zwagemaker, Catherine N. Bagot, Erik A. M. Beckers, Giancarlo Castaman, Marjon H. Cnossen, Peter W. Collins, Charles Hay, Michel Hof, Britta Laros-van Gorkom, Frank W. G. Leebeek, Christoph Male, Karina Meijer, Ingrid Pabinger, Susan Shapiro, Michiel Coppens, Karin Fijnvandraat & Samantha C. Gouw,. (2022) The bleeding phenotype in people with nonsevere hemophilia. Blood Advances 6:14, pages 4256-4265.
Crossref
Crossref
Christine A. Simon, Eloise Salmon, Hailey E. Desmond, Susan F. Massengill, Wilson P. Gipson & Debbie S. Gipson. (2022) The Health Economic Impact of Nephrotic Syndrome in the United States. Kidney360 3:6, pages 1073-1079.
Crossref
Crossref
Kathryn E. Dane, Rakhi P. Naik, Michael B. Streiff, Jennifer Yui, Satish Shanbhag, Todd W. Nesbit & John Lindsley. (2022) Hemostatic and antithrombotic stewardship programs: A toolkit for program implementation. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY 5:6, pages 622-631.
Crossref
Crossref
Michael Recht, Chunla He, Er. Chen, Dunlei Cheng, Paul Solari & David Hinds. (2022) Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset. eJHaem 3:2, pages 341-352.
Crossref
Crossref
Courtney D ThornburgKelly AdamskiKeziah CookMohini VembusubramanianSelvam R SendhilDavid HindsEr ChenJoshua SammonPaul SolariLouis P GarrisonJrJrStacy E Croteau. (2022) Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. Journal of Managed Care & Specialty Pharmacy 28:4, pages 449-460.
Crossref
Crossref
Roberta Gualtierotti, Francesco Tafuri, Sara Arcudi, Pier Luigi Solimeno, Jacopo Acquati, Laura Landi & Flora Peyvandi. (2022) Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy. Pain and Therapy 11:1, pages 1-15.
Crossref
Crossref
Zhengwei Huang, Stephen Nicholas, Yong Yang, Xiaoping Chen, Elizabeth Maitland, Yong Ma & Xuefeng Shi. (2022) Medical costs and hospital utilization for hemophilia A and B urban inpatients in China: a national cross-sectional study. BMC Health Services Research 22:1.
Crossref
Crossref
Chunla HeDavid HindsEdmund PezallaDunlei ChengEr ChenJoshua SammonPaul G SolariMichael Recht. (2022) Health insurance coverage and switching among people with hemophilia A in the United States. Journal of Managed Care & Specialty Pharmacy 28:2, pages 232-243.
Crossref
Crossref
C. Laurendeau, J. Goudemand, M. Trossaert, B. Polack, R. Varin, C. Godard, F. Hadim & B. Detournay. (2021) Costs and management of patients with hemophilia A in France: the Hemraude study. The European Journal of Health Economics 23:1, pages 23-32.
Crossref
Crossref
Lidia García-Pérez, Renata Linertová, Cristina Valcárcel-Nazco, Manuel Posada, Inigo Gorostiza & Pedro Serrano-Aguilar. (2021) Cost-of-illness studies in rare diseases: a scoping review. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Daniel P. Hart, Brian R. Branchford, Sarah Hendry, Robert Ledniczky, Robert F. SidonioJr.Jr., Claude Négrier, Michelle Kim, Michelle Rice, Matthew Minshall, Claire Arcé, Steve Prince, Maria Kelleher & Sharon Lee. (2021) Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Nhan H. Nguyen, Fiona Y. Glassman, Robert K. Dingman, Gautam N. Shenoy, Elizabeth A. Wohlfert, Jason G. Kay, Richard B. Bankert & Sathy V. Balu-Iyer. (2021) Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins. Scientific Reports 11:1.
Crossref
Crossref
Iris van Moort, Tim Preijers, Laura H Bukkems, Hendrika C A M Hazendonk, Johanna G van der Bom, Britta A P Laros-van Gorkom, Erik A M Beckers, Laurens Nieuwenhuizen, Felix J M van der Meer, Paula Ypma, Michiel Coppens, Karin Fijnvandraat, Roger E G Schutgens, Karina Meijer, Frank W G Leebeek, Ron A A Mathôt, Marjon H Cnossen, Marjon H. Cnossen, Frank W.G. Leebeek, Ron A.A. Mathôt, Karin Fijnvandraat, Michiel Coppens, Karina Meijer, Marieke J.H.A. Kruip, Suzanne Polinder, Janske Lock, Hendrika C.A.M. Hazendonk, Iris Van Moort, Jessica M. Heijdra, Marie C.H.J. Goedhart, Wala Al Arashi, Tim Preijers, Nico C.B. De Jager, Laura H. Bukkems, Michael E. Cloesmeijer, Alexander Janssen, Rienk Y.J. Tamminga, Paul Brons, Saskia E.M. Schols, Jeroen C.J. Eikenboom, Felix J.M. Van der Meer, Roger E.G. Schutgens, Kathelijne Fischer, Karin P.M. Van Galen, Erik E.A.M. Beckers, Floor C.J.I. Heubel-Moenen, Laurens Nieuwenhuizen, Paula Ypma, Mariëtte H.E. Driessens, Ineke Van Vliet, Peter W. Collins, Ri Liesner, Pratima Chowdary, Carolyn M. Millar, Dan Hart & David Keeling. (2021) Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. The Lancet Haematology 8:7, pages e492-e502.
Crossref
Crossref
Folashayo Adeniji. (2021) Burden of out-of-pocket payments among patients with cardiovascular disease in public and private hospitals in Ibadan, South West, Nigeria: a cross-sectional study. BMJ Open 11:6, pages e044044.
Crossref
Crossref
Petra Maresova, Lukas Rezny, Lukas Peter, Ladislav Hajek & Frank Lefley. (2021) Do Regulatory Changes Seriously Affect the Medical Devices Industry? Evidence From the Czech Republic. Frontiers in Public Health 9.
Crossref
Crossref
Stacy E CroteauKeziah CookLamiya SheikhAnita ChawlaJoshua SammonPaul Solari, Benjamin KimDavid HindsCourtney D Thornburg. (2021) Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. Journal of Managed Care & Specialty Pharmacy 27:3, pages 316-326.
Crossref
Crossref
Hanna Ventola, Aino Vesikansa, Jari Jokelainen, Timo Siitonen, Pia Ettala, Outi Laine, Elina Lehtinen, Aino Lepäntalo, Maria Patronen, Anu Partanen, Miika Linna, Tero Ylisaukko‐oja & Riitta Lassila. (2020) Characterisation of healthcare utilisation and cost of haemophilia care in real‐life: A 4‐year follow‐up study in Finland. Haemophilia 27:1.
Crossref
Crossref
Jeffrey S. Stonebraker & Jonathan M. Ducore. (2020) Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres. Haemophilia 27:1.
Crossref
Crossref
Hankil Lee, Hyeonseok Cho, Jung Woo Han, Ah‐Young Kim, Seonyoung Park, Minjun Lee, Sunghwa Cho, Deborah Baik & Hye‐Young Kang. (2020) Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea. Haemophilia 27:1.
Crossref
Crossref
Luisa Fernanda Alvis, Patricia Sánchez, Lizbeth Acuña, Germán Escobar, Adriana Linares, María Helena Solano & Sergio Robledo. (2020) National registry of haemophilia and other coagulopathies: A multisector initiative in the Colombian Health System. Haemophilia 26:6.
Crossref
Crossref
Zheng-Yi ZhouKarina RaimundoAnisha M. PatelSimeng HanYusi JiHonghao FangJia ZhongKeith A. BettsArash Mahajerin. (2020) Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A. Journal of Managed Care & Specialty Pharmacy 26:9, pages 1109-1120.
Crossref
Crossref
Laurie J. Brown, Hai A. La, Jinjing Li, Matthias Brunner, Martin Snoke & Annette M. Kerr. (2020) The societal burden of haemophilia A. I – A snapshot of haemophilia A in Australia and beyond. Haemophilia 26:S5, pages 3-10.
Crossref
Crossref
Laurie J. Brown, Hai A. La, Jinjing Li, Matthias Brunner, Martin Snoke & Annette M. Kerr. (2020) The societal burden of haemophilia A. II – The cost of moderate and severe haemophilia A in Australia. Haemophilia 26:S5, pages 11-20.
Crossref
Crossref
Laurie J. Brown, Hai A. La, Jinjing Li, Matthias Brunner, Martin Snoke & Annette M. Kerr. (2020) The societal burden of haemophilia A. III – The potential impact of emicizumab on costs of haemophilia A in Australia. Haemophilia 26:S5, pages 21-29.
Crossref
Crossref
Ryan Farej, Katharine Batt, Olubunmi Afonja, Carolyn Martin, Ronald Aubert, Maureen Carlyle, John White & Robert F. SidonioJrJr. (2020) Characterizing female patients with haemophilia A: Administrative claims analysis and medical chart review. Haemophilia 26:3, pages 520-528.
Crossref
Crossref
Amit Chhabra, Dean Spurden, Patrick F. Fogarty, Bartholomew J. Tortella, Emily Rubinstein, Simon Harris, Andreas M. Pleil, Jennifer Mellor, Jonathan de Courcy & José Alvir. (2020) Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagulation & Fibrinolysis 31:3, pages 186-192.
Crossref
Crossref
John S.S. Butterfield, Kerry M. Hege, Roland W. Herzog & Radoslaw Kaczmarek. (2020) A Molecular Revolution in the Treatment of Hemophilia. Molecular Therapy 28:4, pages 997-1015.
Crossref
Crossref
Guillaume Carmona & Devyn M. Smith. 2020. Second Generation Cell and Gene-based Therapies. Second Generation Cell and Gene-based Therapies
409
432
.
Andreia Café, Manuela Carvalho, Miguel Crato, Miguel Faria, Paula Kjollerstrom, Cristina Oliveira, Patrícia R. Pinto, Ramón Salvado, Alexandra Aires dos Santos & Catarina Silva. (2019) Haemophilia A: health and economic burden of a rare disease in Portugal. Orphanet Journal of Rare Diseases 14:1.
Crossref
Crossref
Menaka Pai, Cindy H. T. Yeung, Elie A. Akl, Andrea Darzi, Christopher Hillis, Kimberly Legault, Joerg J. Meerpohl, Nancy Santesso, Domenica Taruscio, Madeleine Verhovsek, Holger J. Schünemann & Alfonso Iorio. (2019) Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. BMC Medical Research Methodology 19:1.
Crossref
Crossref
Martin Rodriguez, Christopher D. Porada & Graça Almeida-Porada. (2019) Mechanistic Insights into Factor VIII Immune Tolerance Induction via Prenatal Cell Therapy in Hemophilia A. Current Stem Cell Reports 5:4, pages 145-161.
Crossref
Crossref
Flora Peyvandi, Fatemeh Tavakkoli, Diana Frame, Jennifer Quinn, Benjamin Kim, Adebayo Lawal, Mimi C. Lee & Wing Y. Wong. (2019) Burden of mild haemophilia A: Systematic literature review. Haemophilia 25:5, pages 755-763.
Crossref
Crossref
Denise E. Sabatino, Steven W. Pipe, Diane J. Nugent, J. Michael Soucie, W. Craig Hooper, W. Keith Hoots & Donna M. DiMichele. (2019) Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors. Haemophilia 25:4, pages 575-580.
Crossref
Crossref
Koyo Usuba, Victoria E. Price, Victor Blanchette, Audrey Abad, Carmen Altisent, Loretta Buchner‐Daley, Jorge D.A. Carneiro, Brian M. Feldman, Kathelijn Fischer, John Grainger, Susanne Holzhauer, Koon‐Hung Luke, Sandrine Meunier, Margareth Ozelo, Ling Tang, Sandra V. Antunes, Paula Villaça, Cindy Wakefield, Gilian Wharfe, Runhui Wu & Nancy L. Young. (2019) Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries. Research and Practice in Thrombosis and Haemostasis 3:3, pages 397-404.
Crossref
Crossref
Ryan E. Wiley, Charles P. Khoury, Adrian W. K. Snihur, Marni Williams, David Page, Nicole Graham, Lori Laudenbach, Cindy Milne‐Wren & Jayson M. Stoffman. (2019) From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia 25:3, pages 433-440.
Crossref
Crossref
Rebecca A. Malouin, Laurel Mckernan, Ann Forsberg, Dunlei Cheng, John Drake, Kathryn McLaughlin & Marisela Trujillo. (2018) Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States. Maternal and Child Health Journal 22:9, pages 1240-1246.
Crossref
Crossref
Víctor Jiménez-Yuste, María Teresa Álvarez Román, María Eva Mingot-Castellano, Nuria Fernández Mosteirin, María Mareque & Itziar Oyagüez. (2018) Análisis de costes del tratamiento para pacientes con hemofilia A con inhibidor en España. PharmacoEconomics Spanish Research Articles 15:1-4, pages 25-34.
Crossref
Crossref
Teja ThoratPeter J. NeumannJames D. Chambers. (2018) Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia. Journal of Managed Care & Specialty Pharmacy 24:7, pages 632-642.
Crossref
Crossref
Brian M Feldman, Georges E Rivard, Paul Babyn, John K M Wu, MacGregor Steele, Man-Chiu Poon, Robert T Card, Sara J Israels, Nicole Laferriere, Kulwant Gill, Anthony K Chan, Manuel Carcao, Robert J Klaassen, Stephanie Cloutier, Victoria E Price, Saunya Dover & Victor S Blanchette. (2018) Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. The Lancet Haematology 5:6, pages e252-e260.
Crossref
Crossref
S. Nguyen, X. Lu, Y. Ma, J. Du, E.Y. Chang & A. von Drygalski. (2018) Musculoskeletal ultrasound for intra‐articular bleed detection: a highly sensitive imaging modality compared with conventional magnetic resonance imaging. Journal of Thrombosis and Haemostasis 16:3, pages 490-499.
Crossref
Crossref
Pauline Balkaransingh & Guy Young. (2017) Novel therapies and current clinical progress in hemophilia A. Therapeutic Advances in Hematology 9:2, pages 49-61.
Crossref
Crossref
Steven W. Pipe. (2018) Gene therapy for hemophilia. Pediatric Blood & Cancer 65:2, pages e26865.
Crossref
Crossref
Jamie O’Hara, David Hughes, Charlotte Camp, Tom Burke, Liz Carroll & Daniel-Anibal Garcia Diego. (2017) The cost of severe haemophilia in Europe: the CHESS study. Orphanet Journal of Rare Diseases 12:1.
Crossref
Crossref
M. Ullman, Q. C. Zhang, S. D. Grosse, M. Recht & J. M. Soucie. (2017) Prophylaxis use among males with haemophilia B in the United States. Haemophilia 23:6, pages 910-917.
Crossref
Crossref
Christina X. Chen, Judith R. Baker & Michael B. Nichol. (2017) Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates. Value in Health 20:8, pages 1074-1082.
Crossref
Crossref
Susanne Mayer, Aggie T. G. Paulus, Agata Łaszewska, Judit Simon, Ruben M. W. A. Drost, Dirk Ruwaard & Silvia M. A. A. Evers. (2017) Health-Related Resource-Use Measurement Instruments for Intersectoral Costs and Benefits in the Education and Criminal Justice Sectors. PharmacoEconomics 35:9, pages 895-908.
Crossref
Crossref
A. Shrestha, A. Eldar-Lissai, N. Hou, D.N. Lakdawalla & K. Batt. (2017) Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia 23:4, pages e267-e275.
Crossref
Crossref
Sarena D. Horava & Nicholas A. Peppas. (2017) Recent advances in hemophilia B therapy. Drug Delivery and Translational Research 7:3, pages 359-371.
Crossref
Crossref
Tom MunyerSheh-Li Chen & Amanda Cass. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.
A. Zakieh & A. H. Siddiqui. (2017) Emergency department utilization by haemophilia patients in United States. Haemophilia 23:3, pages e188-e193.
Crossref
Crossref
Suzanne McMullen, Brieana Buckley, Eric HallIIII, Jon Kendter & Karissa Johnston. (2017) Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States. Value in Health 20:1, pages 93-99.
Crossref
Crossref
Renata Linertová, Lidia García-Pérez & Iñigo Gorostiza. 2017. Rare Diseases Epidemiology: Update and Overview. Rare Diseases Epidemiology: Update and Overview
283
297
.
A.H. Miners, S. Krishnan & K.J. Pasi. (2016) Predicting the outcomes of using longer‐acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis. Journal of Thrombosis and Haemostasis 14:11, pages 2141-2147.
Crossref
Crossref
P. de Kleijn, E. P. Mauser-Bunschoten, K. Fischer, C. Smit, H. Holtslag & C. Veenhof. (2016) Evidence for and cost-effectiveness of physiotherapy in haemophilia: a Dutch perspective. Haemophilia 22:6, pages 943-948.
Crossref
Crossref
Sabina Shrestha, Sufang Dong, Zuhua Li, Zhuliang Huang & Fang Zheng. (2016) Evaluation of factor VIII polymorphic short tandem repeat markers in linkage analysis for carrier diagnosis of hemophilia A. Biomedical Reports 5:2, pages 228-232.
Crossref
Crossref
Chiai Nagae, Atsuki Yamashita, Tomoko Ashikaga, Mika Mori, Mieko Akita, Kaoru Kitsukawa, Satoshi Yamazaki, Kimie Yoshikawa & Masashi Taki. (2016) A cohort study of the usefulness of primary prophylaxis in patients with severe haemophilia A. International Journal of Hematology 104:2, pages 208-215.
Crossref
Crossref
M. Pai, N. S. Key, M. Skinner, R. Curtis, M. Feinstein, C. Kessler, S. J. Lane, M. Makris, E. Riker, N. Santesso, J. M. Soucie, C. H. T. Yeung, A. Iorio & H. J. Schünemann. (2016) NHF-McMaster Guideline on Care Models for Haemophilia Management. Haemophilia 22, pages 6-16.
Crossref
Crossref
Eberechukwu Onukwugha, Jacquelyn McRae, Alex Kravetz, Stefan Varga, Rahul Khairnar & C. Daniel Mullins. (2015) Cost-of-Illness Studies: An Updated Review of Current Methods. PharmacoEconomics 34:1, pages 43-58.
Crossref
Crossref